Skip to main content
Premium Trial:

Request an Annual Quote

Shi Chung Ng, Mark Pittenger, Katherine Hilyard, Dan Calvo

Premium
CytRx this week announced that Shi Chung Ng has joined the company in the newly created position of senior vice president of research and development, reporting to Chief Scientific Officer Jack Barber. Ng will be based in CytRx's new San Diego research and development facility, which is scheduled to open in the third quarter.
 
Ng was previously vice president of molecular oncology at Ligand Pharmaceuticals. Prior to that, he was vice president of drug discovery biology and preclinical development at Arqule.
 

 
Opexa Therapeutics this week named Mark Pittenger to its scientific advisory board. Pittenger was previously vice president of research and part of the senior management team at Osiris Therapeutics.
 
Pittenger is a senior director at Life Sciences Technologies Partners and an adjunct assistant professor at Johns Hopkins University.
 

 
Galapagos this week announced that Katherine Hilyard has been appointed as vice president for biological sciences for its BioFocus DPI business unit.
 
Hilyard will report to Chris Newton, senior vice president of BioFocus DPI. Hilyard has 11 years of experience in the pharma and biotech industries, including Hoffmann-La Roche and Cambridge Antibody Technology, where she was director of discovery biology.
 
Galapagos also announced that it has recruited Clinquest to help the company prepare clinical trials for its pipeline of bone and joint disease therapeutics. Cees Wortel from Clinquest will serve as acting chief medical officer for Galapagos.
 
Wortel has over 19 years of product development experience with pharmaceutical and biotech companies, including Centocor and Alkermes.
 

 
Optra Systems last week named Dan Calvo chairman of its board of directors. The company board passed a resolution to this effect in its meeting last week.
 
Calvo was recently named president and CEO of Assay Designs. He was previously CEO of Cellomics.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.